CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
This certification will open new markets for the Kwality Pharma
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated